Related Experiment Video
Updated: May 5, 2026

Affinity Purification of Influenza Virus Ribonucleoprotein Complexes from the Chromatin of Infected Cells
Published on: June 3, 2012
Amphotericin B increases influenza A virus infection by preventing IFITM3-mediated restriction
Tsai-Yu Lin1, Christopher R Chin2, Aaron R Everitt3
1Department of Microbiology and Physiological Systems, University of Massachusetts Medical School, Worcester, MA 01655, USA.
Abstract:
The IFITMs inhibit influenza A virus (IAV) replication in vitro and in vivo. Here, we establish that the antimycotic heptaen, amphotericin B (AmphoB), prevents IFITM3-mediated restriction of IAV, thereby increasing viral replication. Consistent with its neutralization of IFITM3, a clinical preparation of AmphoB, AmBisome, reduces the majority of interferon's protective effect against IAV in vitro. Mechanistic studies reveal that IFITM1 decreases host-membrane fluidity, suggesting both a possible mechanism for IFITM-mediated restriction and its negation by AmphoB. Notably, we reveal that mice treated with AmBisome succumbed to a normally mild IAV infection, similar to animals deficient in Ifitm3. Therefore, patients receiving antifungal therapy with clinical preparations of AmphoB may be functionally immunocompromised and thus more vulnerable to influenza, as well as other IFITM3-restricted viral infections.
Insights
Amphotericin B (AmphoB), an antifungal drug, unexpectedly enhances influenza A virus (IAV) replication by blocking IFITM3's antiviral activity. This finding suggests patients on AmphoB therapy may be more vulnerable to IAV infections.
Area of Science:
- Virology
- Immunology
- Pharmacology
Background:
- Interferon-induced transmembrane proteins (IFITMs) are crucial for innate immunity against influenza A virus (IAV).
- IFITM3 specifically restricts IAV replication, contributing to host defense.
- The precise mechanisms by which IFITMs exert their antiviral effects are still being elucidated.
Purpose of the Study:
- To investigate the effect of the antifungal drug amphotericin B (AmphoB) on IFITM-mediated restriction of IAV.
- To determine if clinical preparations of AmphoB impact host defense against IAV.
- To elucidate the mechanism by which AmphoB interferes with IFITM antiviral activity.
Main Methods:
- In vitro assays measuring IAV replication in the presence of IFITM proteins and AmphoB.
- In vivo studies using a mouse model of IAV infection treated with AmBisome (a clinical AmphoB preparation).
- Analysis of host membrane fluidity in response to IFITM1 expression and AmphoB treatment.
Main Results:
- AmphoB and its clinical formulation AmBisome prevent IFITM3-mediated restriction of IAV, leading to increased viral replication.
- AmphoB neutralizes the protective effect of interferon against IAV in vitro.
- IFITM1 was found to decrease host membrane fluidity, a property negated by AmphoB.
- Mice treated with AmBisome exhibited increased susceptibility to IAV infection, mirroring outcomes in Ifitm3-deficient mice.
Conclusions:
- AmphoB interferes with the antiviral functions of IFITM proteins, particularly IFITM3.
- Clinical use of AmphoB may compromise host defense against IAV and potentially other IFITM3-restricted viruses.
- Patients undergoing antifungal therapy with AmphoB may be functionally immunocompromised, increasing their vulnerability to viral infections.
Related Concept Videos
Antifungal Agents
Influenza
Antimicrobial Proteins
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
Inhibitors of Viral Protein Synthesis
Leaky Scanning
Immune Response Against Viral Pathogens
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...

